Wolters Kluwer Health, a provider of clinical decision support solutions, has announced significant milestones for AI Labs, its Clinical Generative AI (GenAI) beta launched in 2023 and powered by UpToDate®. This initiative strengthens Wolters Kluwer's position as a leader in the Clinical GenAI market and underscores its commitment to delivering innovative solutions for healthcare professionals.
AI Labs now boasts access to UpToDate's comprehensive collection of evidence-based clinical content and graded recommendations spanning over 25 medical specialties, making it the only large language model (LLM) exclusively powered by UpToDate's trusted content.
The launch of UpToDate Enterprise™ Edition marks another milestone, providing over 100 U.S. hospitals and major health systems with access to AI Labs' testing and validation program. This program is instrumental in ensuring the responsible development and deployment of Clinical GenAI as a trusted point-of-care solution.
AI Labs has achieved significant advancements in Clinical GenAI innovation, including verbatim UpToDate passage retrieval and AI-synthesized responses based exclusively on UpToDate's unparalleled content. By leveraging natural language processing, AI Labs delivers targeted answers derived from UpToDate's continually updated content, ensuring clinicians access the most relevant and up-to-date information.
Customer feedback plays a crucial role in the ongoing development of AI Labs, with healthcare professionals expressing optimism about the potential of GenAI in clinical decision support. Eric Alper, MD, Senior Vice President and Chief Quality Officer at UMass Memorial Health, highlighted the ability of GenAI to expedite access to expert, evidence-based content for clinicians.
Recognizing Wolters Kluwer Health's pioneering approach to GenAI, industry analysts at Frost & Sullivan recently named the company a healthcare technology pioneer for GenAI in clinical settings.
Click here to read the original press release.
More News in this Theme
